What is Sub-Q Bionics?
Sub-Q Bionics is a medical technology company dedicated to addressing lymphedema, a chronic condition that frequently affects cancer survivors. The companys innovative technology centers on an implantable device designed to facilitate lymphatic circulation. This system operates beneath the skin to aid in the movement of lymphatic fluid, thereby mitigating the swelling, discomfort, and mobility issues characteristic of the disease. Headquartered in Stillwater, Minnesota, Sub-Q Bionics aims to provide a novel therapeutic solution for patients suffering from this debilitating condition.
How much funding has Sub-Q Bionics raised?
Sub-Q Bionics has raised a total of $1.5M across 1 funding round:
Angel/Pre-Seed
$1.5M
Angel/Pre-Seed (2026): $1.5M with participation from Yeda Research and Development and Mayo Clinic
Key Investors in Sub-Q Bionics
Yeda Research and Development
Yeda Research and Development is the commercialization arm of the Weizmann Institute of Science, focusing on translating scientific discoveries into market-ready technologies across various sectors including MedTech and BioPlatforms. Their involvement indicates a strong belief in the scientific underpinnings of Sub-Q Bionics' innovative medical device.
Mayo Clinic
Mayo Clinic, a world-renowned nonprofit healthcare organization, contributes its expertise in clinical practice and medical research. Their participation highlights the potential clinical impact and therapeutic value of Sub-Q Bionics' lymphedema management system.
What's next for Sub-Q Bionics?
With this substantial backing, Sub-Q Bionics is poised for significant advancement in its product development and market penetration strategies. The major strategic investment suggests a focus on scaling operations, potentially expanding clinical trials, and preparing for regulatory approvals. This funding will likely accelerate the companys mission to bring its implantable lymphatic drainage system to market, offering a new avenue for managing lymphedema and improving the quality of life for affected individuals, particularly those who have undergone cancer treatment.
See full Sub-Q Bionics company page
